Toward Durable Disease Control in EGFR-Mutant (mt) NSCLC: Interpreting the Survival Signals from FLAURA2 and MARIPOSA

EGFR-mutant non-small cell lung cancer (NSCLC) has long served as a model for precision oncology. The introduction of third-generation tyrosine kinase inhibitors (TKIs), particularly osimertinib, established a standard of care characterized by high response rates, central nervous system (CNS) penetration, and median overall survival (OS) approaching 40 months in the first-line setting.1

Despite these advances, resistance remains nearly universal. The central challenge has therefore shifted from identifying the correct target to preventing tumor evolution beyond it.

Two phase III trials—FLAURA2 and MARIPOSA—directly addressed this challenge by evaluating upfront combination strategies.2,3 FLAURA2 combined osimertinib with platinum-based pemetrexed chemotherapy, while MARIPOSA paired the EGFR-MET bispecific antibody amivantamab with lazertinib, a TKI very similar to osimertinib with respect to activity and toxicity.

Both demonstrated improved progression-free survival (PFS) and OS compared with osimertinib monotherapy for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution, but both did so through fundamentally distinct biological strategies. Understanding these differences is essential as the field moves toward more durable disease control.

A Therapeutic Ceiling: Why Monotherapy is Not Enough

EGFR-mutant NSCLC is characterized by initial sensitivity to targeted therapy followed by adaptive resistance. This process reflects a continuum shaped by tumor heterogeneity, selective pressure, and the presence of drug-tolerant persister (DTP) cells.

DTPs survive initial therapy through reversible, non-genetic mechanisms such as chromatin remodeling, metabolic reprogramming, and lineage plasticity, and they serve as a reservoir from which stable resistance mechanisms emerge, including EGFR C797S mutations, MET amplification, and histologic transformation.4,5

While monotherapy effectively suppresses the dominant oncogenic driver, it does not eliminate these residual populations. Treatment failure is therefore often seeded early, long before clinical progression becomes apparent. Upfront combination strategies aim to intervene at this stage, either by reducing the overall burden of residual disease or by blocking key escape pathways.

FLAURA2: Broad Suppression Through Chemotherapy

FLAURA2 evaluated the addition of platinum-pemetrexed induction with maintenance pemetrexed to osimertinib. The combination significantly improved median PFS (25.5 months vs. 16.7 months; HR 0.62; p = 0.001) and OS (47.5 months vs. 37.6 months; HR 0.77; p = 0.02).

Among patients with baseline brain metastases, median PFS improved from 13.8 months to 24.9 months (HR 0.56), with a corresponding increase in duration of response, supporting clinically meaningful intracranial disease control. This benefit was consistent across prognostic groups, spanning those with or without brain, liver, or bone metastases, EGFR mutation subtype, and TP53 co-alteration status.6

Toxicity was increased, with grade 3 or higher adverse events (AEs) reported in approximately 70% of patients, compared to 27% in the monotherapy arm. These were largely driven by myelosuppression and gastrointestinal toxicity and primarily confined to the first four cycles of the induction phase.

Biologically, this regimen reflects a strategy of broad suppression of tumor evolution. Chemotherapy exerts a non-selective cytotoxic effect across proliferating tumor populations, independent of specific resistance mechanisms.

This may reduce both dominant clones and DTPs, thereby limiting the substrate for future resistance. The “catch-all” approach and observed survival benefit across heterogeneous subgroups support applicability in the absence of predictive biomarkers.

MARIPOSA: Targeted Inhibition of a Dominant Escape Pathway

MARIPOSA evaluated amivantamab combined with lazertinib, targeting both EGFR and MET signaling. The regimen improved median PFS (23.7 months vs. 16.6 months; HR 0.70; p = 0.001) and OS (HR 0.75, p = 0.005), with 3-year survival rates of 60% versus 51%.

Median OS was not reached at the time of analysis, with a projected benefit exceeding 12 months predicted by parametric modeling. Prolonged PFS was also observed for patients with baseline CNS metastases (18.3 months vs. 13 months; HR 0.69), and overall benefit was seen across key subgroups including patients with liver metastases, TP53 co-mutations, and detectable circulating tumor DNA (ctDNA).

Toxicity differed from chemotherapy-based approaches. Grade 3 or higher AEs occurred in approximately 75% of patients and included dermatologic toxicity, infusion-related reactions, and an increased incidence of venous thromboembolism. Structured prophylactic dermatologic management and anticoagulation can mitigate these risks and improve tolerability, as shown prospectively in the COCOON trial.7

In contrast to FLAURA2, MARIPOSA represents a strategy of targeted evolutionary constraint. MET amplification is one of the most common bypass resistance mechanisms following osimertinib, occurring in up to 25% of patients.8 By simultaneously inhibiting EGFR and MET signaling, this approach aims to suppress this pathway before it becomes clinically dominant.

CtDNA analyses show reduced emergence of complex, multi-pathway resistance compared with osimertinib alone (28% vs. 43%). In addition, amivantamab may engage immune effector mechanisms such as antibody-dependent cellular cytotoxicity and trogocytosis, a process where one cell extracts membrane fractions from donor cells, ultimately introducing a potential immunologic dimension to disease control.9

Although it is biologically plausible that patients with MET-altered disease may preferentially benefit from this strategy, supported by post-osimertinib data from the CHRYSALIS-2 study and preclinical findings,10,11 this remains unproven in the first-line setting.

Not the Same: Mechanism and Survival in Context

Although both regimens improve outcomes, they are not interchangeable. Rather, they represent distinct strategies to delay resistance: One through broad suppression of heterogeneous tumor populations, the other through targeted inhibition of a dominant escape route.

At present, there are no validated biomarkers to guide selection between these two approaches. There are also no direct comparisons, and cross-trial interpretation should be approached cautiously given differences in study design and data maturity.

These trials highlight a conceptual shift in the evaluation of survival benefit in oncogene-addicted lung cancer. Gains are no longer driven solely by depth of initial response, but by durability of disease control over time, shaped by the interplay between resistance and treatment tolerability. This underscores the importance of mature follow-up and the need for surrogate endpoints that better reflect the timing and accumulation of benefit—dimensions not fully captured by hazard ratios alone.

Restricted mean survival time offers a complementary lens, particularly when hazards are non-proportional. In both FLAURA2 and MARIPOSA, analyses show early overlap followed by delayed separation of survival curves, with differences emerging only after extended follow-up.

This pattern suggests that benefit accrues with time and supports interest in response-guided strategies to better define when and for whom intensification provides advantage.12 Sequencing considerations add further complexity, as MET-directed therapies retain activity after osimertinib and may influence how these strategies are deployed over the disease trajectory.13,14

Translating Evidence into Clinical Decisions

In clinical practice, these approaches are likely to be complementary. The osimertinib-chemotherapy combination offers a broadly effective strategy supported by mature survival data and may be particularly relevant for patients with CNS involvement. The amivantamab-lazertinib combination provides a chemotherapy-free alternative that can be administered subcutaneously or intravenously.

Each regimen introduces distinct toxicities and logistical considerations. Chemotherapy introduces time-limited but intensive toxicity, whereas antibody-based therapy requires ongoing administration, monitoring, and supportive care.

Treatment selection should incorporate not only efficacy but also feasibility. Patient preference, caregiver burden, access to care, institutional resources, and the ability to manage cumulative toxicity must be carefully considered. Importantly, osimertinib monotherapy remains an appropriate option for selected patients, particularly those prioritizing tolerability or for whom combination therapy is not feasible.15

Future Directions: Toward Durable Disease Control

FLAURA2 and MARIPOSA represent a defining step toward durable disease control. Nevertheless, resistance remains expected. Further advances will depend on understanding what persists after initial response and how it shapes long-term outcomes.

A central challenge is the detection and characterization of residual disease, which is not captured by conventional response metrics. Addressing this gap will be essential to better define the timing of intervention and durability of benefit and to guide more effective strategies.

Dynamic biomarkers will be central to this effort. Increasingly sensitive ctDNA assays offer a window into treatment response beyond radiographic endpoints and may help identify early persistence and emerging resistance.

Therapeutic strategies will continue to expand beyond TKIs, with antibody-drug conjugates, bispecific antibodies, and rational mechanistic and orthogonal combinations entering clinical practice. Local therapies continue to supplement systemic lines of care, with careful attention to timing and extent. Achieving durable disease control may also require more effective engagement of the immune system within a historically immune-refractory setting.

Ultimately, progress will depend not only on developing new therapies, but on understanding when and how to use them—aligning treatment to evolving disease biology rather than fixed lines of care. Integration of real-world data with advanced analytic measures, including artificial intelligence, further supports this shift toward more precise and adaptive treatment strategies.

Conclusion

FLAURA2 and MARIPOSA demonstrate that upfront combination therapy can extend disease control in EGFR-mutant NSCLC, each reflecting a distinct biological strategy. The field is moving beyond sequential therapy that reacts to resistance toward approaches that anticipate tumor evolution.

Achieving durable disease control will not come from applying uniform intensification across patients but rather will require treatment paradigms that are biologically informed, adaptable, and aligned to both the individual patient and the evolving tumor landscape.

---

References

• 1. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50.
• 2. Jänne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026;394(1):27-38.
• 3. Yang JC, Lu S, Hayashi H, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693.
• 4. Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. J Thorac Oncol. 2021;16(11):1798-1809.
• 5. Russo M, Chen M, Mariella E, et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer. 2024;24(10):694-717.
• 6. Jänne PA, Planchard D, Kobayashi K, et al: FLAURA2: exploratory overall survival analyses in patients with poorer prognostic factors treated with Osimertinib +/- platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC. 2025 ESMO Congress. Abstract LBA77. Presented October 17, 2025.
• 7. Cho B, Li W, Spira A, et al. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. Journal of Thoracic Oncology, 2025; 20, 1517-1530.
• 8. Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON. Cancer Discov. 2023;13(1):98-113.
• 9. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056.
• 10. Yoshichika R, Mukohara F, Yamada K, et al. Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer. Cancer Immunol Immunother. 2026;75(4):121. Published 2026 Mar 24.
• 11. Besse B, Baik CS, Marmarelis ME, et al. Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS. J Clin Oncol. 2023;41:16s (suppl; abstr 9013).
• 12. Acker F, Rost M, Sebastian M, Cortellini A. Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA. Ann Oncol. 2026;37(1):125-127.
• 13. Wu YL, Guarneri V, Voon PJ, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024;25(8):989-1002.
• 14. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 2024;35:77-90.
• 15. Puri S, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026